Sylvania, OH, United States of America

Jerzy Jankun

USPTO Granted Patents = 3 

Average Co-Inventor Count = 2.9

ph-index = 2

Forward Citations = 19(Granted Patents)


Company Filing History:


Years Active: 1997-2012

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Jerzy Jankun: Innovator in Modified Plasminogen Activator Inhibitor Research

Introduction

Jerzy Jankun is a notable inventor based in Sylvania, OH (US), recognized for his contributions to the field of biochemistry and pharmaceuticals. He holds a total of 3 patents, focusing on modified plasminogen activator inhibitors and their therapeutic applications. His work has significant implications for treating various medical conditions associated with angiogenesis and cardiovascular diseases.

Latest Patents

Jankun's latest patents include innovative methods and compositions related to modified plasminogen activator inhibitor type-1 (PAI-1) molecules. One of his inventions describes a modified PAI-1 molecule that exhibits an increased in vivo half-life while being deficient in certain functional activities compared to the wild-type PAI-1 protein. This modified molecule has potential applications in pharmaceutical compositions aimed at treating conditions such as psoriasis, chronic inflammation, and tumor invasion. Another patent focuses on the discovery that modified PAI-1, where specific amino acid residues are replaced to form intramolecular disulfide bonds, also shows an increased half-life. This invention opens avenues for therapeutics targeting cardiovascular diseases related to hyperfibrinolysis and vessel leakage syndrome.

Career Highlights

Throughout his career, Jerzy Jankun has worked with esteemed institutions such as the University of Toledo and the Medical College of Ohio. His research has contributed to advancements in understanding the role of PAI-1 in various pathological conditions, enhancing the potential for innovative treatments.

Collaborations

Jankun has collaborated with notable colleagues, including Ewa Skrzypczak-Jankun and Steven H Selman, further enriching his research endeavors and expanding the impact of his work in the scientific community.

Conclusion

Jerzy Jankun's innovative research in modified plasminogen activator inhibitors has paved the way for new therapeutic strategies in treating critical health conditions. His contributions continue to influence the fields of biochemistry and pharmaceuticals, showcasing the importance of innovation in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…